Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX with Dabrafenib and Cetuximab/Panitumumab in BRAF V600E MSS mCRC
NCT06978400Phase 2Recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, KL-140, panitumumab in colorectal cancer (CRC), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Mar 2025; status: recruiting.
02
Drugs
dabrafenib + trametinibKL-140panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06978400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978400.